Shah Amil M, Estes N A Mark, Weinstock Jonathan, Homoud Munther K, Link Mark S
Tufts-New England Medical Center, Cardiac Arrhythmia Service, Division of Cardiology, 750 Washington Street, Box # 197, Boston, MA 02111, USA.
Curr Treat Options Cardiovasc Med. 2006 Sep;8(5):353-61. doi: 10.1007/s11936-006-0039-1.
Ventricular arrhythmias and sudden cardiac death in the athlete are uncommon but extremely visible because of the high profile of amateur and professional athletes. In athletes under the age of 30 years, the incidence of sudden death is low and in most cases occurs in individuals with inherited heart disease. In the older athlete, sudden death is more common and is generally due to arrhythmias in the context of coronary artery disease. Many athletes with aborted sudden death, arrhythmia-related syncope, or high-risk genetic disorders benefit from therapy with implantable cardioverter-defibrillators (ICDs). Although ICD therapy can effectively abort sudden death, implantation of an ICD generally prohibits an individual from all competitive athletics except low-intensity sports. Recommendations for participation in competitive athletics generally follow the recently published 36th Bethesda Conference Eligibility Recommendations for Competitive Athletes with Cardiovascular Abnormalities.
运动员发生室性心律失常和心源性猝死虽不常见，但由于业余和职业运动员备受瞩目，所以这类事件格外引人关注。在30岁以下的运动员中，猝死发生率较低，且多数情况发生在患有遗传性心脏病的个体身上。在年龄较大的运动员中，猝死更为常见，通常是由冠状动脉疾病引发的心律失常所致。许多有过猝死未遂、心律失常相关晕厥或高危遗传性疾病的运动员受益于植入式心律转复除颤器（ICD）治疗。尽管ICD治疗能有效预防猝死，但植入ICD通常会禁止个体参加除低强度运动外的所有竞技体育项目。关于参加竞技体育的建议一般遵循最近发布的第36届贝塞斯达会议《心血管异常竞技运动员资格推荐》。
